[PDF] Top 20 Tensiones entre teoría y práctica a propósito de la formación inicial de los profesores
Has 10000 "Tensiones entre teoría y práctica a propósito de la formación inicial de los profesores" found on our website. Below are the top 20 most common "Tensiones entre teoría y práctica a propósito de la formación inicial de los profesores".
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
... before treatment and $2 relapses in the past 2 years) and the definition of MRI activity in CAMMS223 ($1 contrast-enhancing lesion in 1 of 4 monthly baseline MRIs) may be ...for alemtuzumab should not be ... See full document
93
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations
... score-based matching was used in order to select patient groups with comparable baseline characteristics. Although the ARR decreased in both groups (1.5–0.2 in natalizumab vs 1.3–0.4 in fingolimod), there was a ... See full document
7
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
... disease-modifying treatment (DMT) for relapsing multiple ...Relapsing-Remitting Multiple Sclerosis [CONFIRM]) demonstrated significant efficacy in reducing relapse rate and radiological signs ... See full document
7
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations
... status, treatment guidelines, and the actual postmarketing use can differ from the investigated popula- tion in the pivotal clinical trials, making treatment decisions based on well-defined criteria ...and ... See full document
6
Alemtuzumab for the treatment of multiple sclerosis
... efficacious treatment for active relapsing MS having been shown in robust clinical trials and against an active comparator to significantly reduce relapse rates, MRI outcomes and, at the very least, achieve some ... See full document
15
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
... Abstract: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and mainly affects young ...second-line treatment options, together with the variable course of the ... See full document
6
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
... the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to ...now multiple effective and approved agents for this disease ...best treatment option for their ...cabazitaxel ... See full document
6
Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents
... the patient and health care ...the patient who is considering DMT, who is starting on or switching types of DMT, or who has been on DMT for an established amount of ...the patient feels alone on ... See full document
44
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
... the treatment of ...program, alemtuzumab demonstrated higher efficacy in RRMS compared to IFN β 1a, reducing the risk of relapse and ...with alemtuzumab was seen in the clinical ...with ... See full document
73
<p>Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations</p>
... of multiple downstream cascades such as PI3K/AKT and MAPK/ERK pathways, inducing angio- genesis, cell proliferation, invasion and ...sorafenib treatment involves upregulation of HGF secretion and c-MET ... See full document
13
Treatment selection and experience in multiple sclerosis: survey of neurologists
... medication selection were (in order of importance) efficacy, safety, tolerability, patient preference, and ...to treatment with glatiramer acetate ... See full document
10
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
... Abstract: Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple ...sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes ... See full document
46
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
... then a lower dose in the middle of the afternoon (16 hours) aims to maintain a desired biological effect without caus- ing excessive nycturia. The aquaretic effect does not seem to diminish over time. In the TEMPO 3:4 ... See full document
33
Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
... Interestingly, alemtuzumab continued to slow-down the loss of brain volume over the five years: the mean annual rate of brain volume loss ranged between ... See full document
9
IL 21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath 1H)
... antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing-remitting multiple ...to alemtuzumab, usually targeting the thyroid gland and, more rarely, blood ... See full document
19
Robot-assisted radical cystectomy: patient selection and special considerations
... Abstract: Robot-assisted (RA) procedures are increasingly being performed as minimally invasive surgical approaches. Less insensible losses due to a closed abdomen, smaller incisions with less retractor strain, decreased ... See full document
24
Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
... multiple sclerosis. One Phase II and two Phase III trials of alemtuzumab versus active comparator (interferon beta-1a) have been ...in treatment-naïve patients; one explored patients who had ... See full document
8
Natalizumab in the treatment of multiple sclerosis
... It is clear that regardless of when the reaction occurs, the proper action to take if neutralizing antibodies are present is to discontinue natalizumab therapy. The decision becomes less clear when a patient has a ... See full document
18
Colorectal endoscopic submucosal dissection: patient selection and special considerations
... meticulous patient selection, as well as treatment by interventional endoscopists with expertise in the full range of endoscopic resection ... See full document
96
Patient perceptions of multiple sclerosis and its treatment
... target patient group or not. In the case of multiple sclerosis, almost all non-institutionalized patients are managed in a national network of 44 centers (Observatoire Français de la Sclérose en ... See full document
5
Related subjects